NCT00294866 - Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Kidney Failure

Interventions

DRUG

Paricalcitol

Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.

Trial Locations (6)

Delaware Valley Nephrology, Philadelphia

Nephrology Associates, PC, Nashville

Nephrology Center, Kalamazoo

Southwest Nephrology, Evergreen Park

Tyler Nephrology Associates, Tyler

Nephrology Associates P.A., West Orange